Trabectedin

Drug Profile

Trabectedin

Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; Yondelis

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator University of Illinois
  • Developer European Organisation for Research and Treatment of Cancer; Johnson & Johnson; PharmaMar; Taiho Pharmaceutical
  • Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer; Soft tissue sarcoma
  • Phase III Fallopian tube cancer; Peritoneal cancer
  • Phase II Liposarcoma; Meningioma; Mesothelioma
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 07 Apr 2017 Efficacy data from a clinical trial in Liposarcoma released by PharmaMar
  • 23 Mar 2017 Institut Bergonié, AstraZeneca and PharmaMar plan the TRAMUNE phase I trial for Ovarian cancer and Soft tissue sarcoma (Combination therapy, Metastatic disease, Late-stage disease, Inoperable/unresectable, Second-line therapy or greater) in France (NCT03085225)
  • 10 Mar 2017 Fred Hutchinson Cancer Research Center and National Cancer Institute plan a phase I/II trial for Leiomyosarcoma and Liposarcoma (Metastatic disease, Combination therapy, Late-stage disease) in USA (NCT03074318)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top